Streetbeat News

Analyst Ratings

ALTR

Rosenblatt analyst Blair Abernethy downgraded Altair Engineering (ALTR) from Buy to Neutral but increased the price target from $74 to $88.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 12:09 pm

BA

Northcoast Research analyst Chris Olin downgrades Boeing (NYSE:BA) from Buy to Neutral, indicating a shift in the firm's outlook on the aerospace giant.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 12:06 pm

CVE

UBS analyst Manav Gupta has upgraded Cenovus Energy (CVE) from Neutral to Buy and set a price target of C$31.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 12:01 pm

LUNG

Analyst ratings for Pulmonx (NASDAQ:LUNG) have varied over the last quarter, with a recent shift towards a more positive outlook as evidenced by an increase in the average 12-month price target to $16.00 from $14.75. This change reflects adjustments in ratings and price targets by analysts from Wells Fargo, Stifel, and Piper Sandler, responding to Pulmonx's market dynamics and performance. Despite the positive revenue growth of 9.11% for the last 3 months, Pulmonx faces challenges with a net margin of -72.04%, ROE of -11.38%, and ROA of -7.66%, indicating potential difficulties in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 12:00 pm

PEN

Penumbra (NYSE:PEN) has been analyzed by 6 analysts, showing a mix of bullish to indifferent sentiments. The average 12-month price target is $277.17, up from $259.50, with actions ranging from lowering to raising ratings and price targets by firms like JP Morgan and RBC Capital. Penumbra, a medical device manufacturer, showed a revenue growth of 26.8% as of September 30, 2023, but lags in net margin and ROE compared to industry averages. Its debt-to-equity ratio is below industry average, indicating less reliance on debt financing.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 12:00 pm

HUN

Four analysts have recently updated their ratings and price targets for Huntsman (NYSE:HUN), showing a mix of bullish to bearish sentiments. The average 12-month price target has been raised to $27.25, up 7.58% from the previous $25.33. Analyst actions include both upgrades and downgrades, with price targets ranging from $20.00 to $32.00. Huntsman's financial performance shows challenges in revenue growth and efficiency metrics, but a strong net margin and conservative debt management.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 12:00 pm

BIGC

Analysts have varied opinions on BigCommerce Holdings (NASDAQ:BIGC), with recent ratings ranging from bullish to indifferent. The average 12-month price target is $14.62, up from $11.25, indicating a positive outlook. Financial performance analysis shows a revenue growth of 7.81% but below-average net margin, ROE, and ROA, alongside a high debt-to-equity ratio. The company's SaaS platform supports online stores and cross-channel connections, primarily generating revenue from the Americas-U.S.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 12:00 pm

ITCI

Intra-Cellular Therapies (NASDAQ:ITCI) has seen diverse analyst ratings over the last three months, with a positive shift in the average 12-month price target to $81.88, up 16.97% from $70. The company, focusing on drugs for central nervous system diseases, has shown a notable revenue growth of 75.05% as of September 30, 2023, but struggles with profitability and efficiency metrics. Analysts from firms like Needham, Mizuho, and Goldman Sachs have updated their ratings and price targets, reflecting optimism and caution.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 12:00 pm

IRTC

Analyst ratings for iRhythm Technologies (NASDAQ:IRTC) show a bullish consensus with all 5 analysts giving positive ratings. The 12-month price target has increased by 9.98% to an average of $126.2. The company, specializing in cardiac arrhythmia diagnosis through wearable technology, has seen a revenue growth of 19.96% as of September 30, 2023, but lags in profitability and efficiency metrics compared to industry averages.

Portfolio Pulse from Benzinga Insights

February 23, 2024 | 12:00 pm

SQ

Wells Fargo analyst Andrew Bauch upgrades Block (NYSE:SQ) from Equal-Weight to Overweight and sets a new price target of $95.

Portfolio Pulse from Benzinga Newsdesk

February 23, 2024 | 11:58 am